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Abstract 
Atherosclerotic plaques can form in the blood vessels from particles of cholesterol. These 
plaques are a major cause of cardiovascular disease and have the ability to result in fatal 
cardiovascular events. In researching this topic, PubMed, the Cochrane Library, DynaMed, and 
ClinicalKey were all utilized in finding articles published from 2002 to 2018. There are several 
organizations with conflicting guidelines recommending the use of statin medications in the 
primary prevention of cardiovascular disease. The research evaluated discovers data is 
inconclusive on the benefit of statin medications in this primary prevention as well as the safety 
of long-term statin use. Some experts have suggested statins are over-prescribed as it is one of 
the most commonly prescribed medications in the United States. Statin medications continue to 
be beneficial in the primary prevention of some select patients, but caution should be applied by 
providers when prescribing this medication to their patients when referring to conflicting 
population based guidelines. Providers should identify key risk factors and have conversations 
with their patients on the risks and benefits of statin medications when they are being utilized for 
the primary prevention of cardiovascular disease. 
 
Keywords: statin, HMG-CoA reductase inhibitor, atorvastatin, rosuvastatin, fluvastatin, 
pravastatin, lovastatin, primary prevention, cardiovascular disease, CVD, coronary artery 
disease, adverse effects 
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I. Introduction 
Overview of Topic 
Atherosclerotic plaques can form in the blood vessels from particles of cholesterol. These 
plaques are a major cause of cardiovascular disease (CVD) and have the ability to result in fatal 
cardiovascular events. The cause of this plaque formation is not fully known, but result in 
narrowing and possible occlusion of blood vessels leading to decreased blood supply to the 
tissues. This lack of blood flow results in damage to the existing tissues. If a patient has 
previously had a cardiovascular event or has been diagnosed with CVD, medications to lower 
cholesterol are used as secondary prevention to prevent further cardiovascular events or 
worsening of the CVD. If a patient does not have CVD, statins are used in those determined to be 
at a high risk of developing CVD or having a cardiovascular event (Baron, 2017). The data is 
inconclusive and differ among many studies whether the use of statins is beneficial in primary 
prevention when evaluating the rate of cardiovascular events, CVD mortality and all-cause 
mortality.   
Medications that fall into this class of pharmacological agents are commonly referred to 
as statins and include lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin, and 
rosuvastatin. Statins are also known as 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) 
reductase inhibitors which gives a brief description of their mechanism of action. HMG-CoA 
reductase is an enzyme involved in the first step in the formation of cholesterol in the liver. By 
inhibiting HMG-CoA, the synthesis of cholesterol is reduced, thereby reducing the levels of 
cholesterol found in the blood (Malloy & Kane, 2015). With less cholesterol in the blood, 
atherosclerotic plaques are not as easily formed. Although, as discussed earlier, the cause of the 
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formation of plaque is not fully known and increased levels of cholesterol in the blood can 
increase the likelihood of plaques forming.  
Several different organizations have recommendation guidelines to choose patients who 
may benefit from a statin prescription. The American College of Cardiology (ACC) and 
American Heart Association (AHA) teamed up to develop a risk assessment calculator. Based on 
the percentage of risk of developing cardiovascular disease, the calculator then recommends if 
statins are appropriate for patients. The United States Preventative Services Task Force also uses 
this risk assessment calculator to divide patients into groups to recommend or not recommend 
statin therapies. With these differing recommendation statements, some patients fall into a statin 
therapy benefit group with one organization, but not the other (Pagidaipati, 2017). These 
population-based recommendations have been criticized as it may seem almost all patients can 
fall into one of the treatment groups. The use of statins in the prevention of cardiovascular events 
is difficult to quantify as we still do not know the exact cause of plaque formation or migration 
of plaques resulting in cardiovascular events. There is also lack of information on whether statin 
medications have deleterious long-term effects as the widespread use of statins has been 
somewhat recent in terms of medical research as statins were first approved for use in 1987 
(Baron, 2017).   
Statement of the Problem 
Statin medications have become a mainstay in the primary prevention of CVD. 
Controversy exists on whether cardiovascular events are truly being prevented by the use of 
statins or if these medications are being over-prescribed.  
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Research Question 
 In patients without existing cardiovascular disease, does taking a statin medication (rather 
than not taking a statin medication) prevent cardiovascular events?  
 In patients taking statins, does the benefit of taking statins outweigh the risk of long-term 
statin use in the primary prevention of cardiovascular disease? 
Steps of How Review Was Conducted 
In researching this topic, PubMed, the Cochrane Library, DynaMed, and ClinicalKey 
were all utilized. Keywords searched included: statin, HMG-CoA reductase inhibitor, 
atorvastatin, rosuvastatin, fluvastatin, pravastatin, lovastatin, primary prevention, cardiovascular 
disease, CVD, coronary artery disease, adverse effects, pharmacology, and intensity. Several of 
these keywords were combined applying the Boolean operator “AND” to limit the search. All 
studies included were published in a peer-reviewed source within the last 15 years. 
Organization of Chapters 
 The Introductory section provided a description of the problem and provided 
pharmacological information on statin medications. The Review of Literature section provides 
information about current recommendations for statin use as well as information from several 
peer-reviewed studies which relate to the use of statin medications and the safety of long-term 
statin use. The Discussion section will provide a conversation of these articles and how they 
relate to the primary prevention of cardiovascular disease. Lastly, the Applicability to Clinical 
Practice section will focus on providing practitioners with information on choosing which 
patients are ideal candidates for statin medications and which patients may not see benefit from 
their use. 
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II. Review of Literature 
Background Information 
The efficacy of statins and their effect on cholesterol is determined by evaluating lipids. 
Lipids in the plasma are found in complexes called lipoproteins. These can be further divided 
into low-density lipoproteins (LDL), high-density lipoproteins (HDL), and triglycerides. Lipid 
levels are evaluated in patients after a ten hour fast to avoid alterations in measurements caused 
by food consumption. LDL cholesterol levels, the primary target of statin medications, should be 
below 100 mg/dL, whereas levels above 190 mg/dL are considered very high. HDL cholesterol 
levels are inverse to LDL cholesterol, in which higher levels are optimal. These levels are best 
when measured above 60 mg/dL. Total cholesterol levels are calculated based on an equation 
adding LDL levels, HDL levels and one-fifth of the triglyceride levels. Total cholesterol levels 
below 200 mg/dL are desired. High levels of lipids in the blood is commonly referred to as 
dyslipidemia or hyperlipidemia. Atherosclerosis is a substantial concern related to long-term 
dyslipidemia (Malloy & Kane, 2015).  
The pharmacodynamics of statins is also important when evaluating this class of 
medications, especially when discussing safety. Once statins have been administered, there is 
significant first-pass hepatic uptake. Hepatic synthesis of cholesterol is most active during the 
night, so statins with a low half-life should be administered in the evening. Once entering the 
liver, more than 70% of the medication is excreted by the liver and into the feces. Some adverse 
effects, although rare, include headache, nausea, constipation, myopathy, and elevations in liver 
function tests. Patients should avoid taking statin medications if they are pregnant or 
breastfeeding, if they have unexplained elevated liver function tests, or if they have active liver 
disease. Providers should also take caution in patients with long-term alcohol use. 
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Recommendations for statin prescribing include obtaining a creatinine level and liver function 
tests at baseline and then as clinically indicated (Gurgle & Blumenthal, 2017).   
Statins can be classified by their intensity, or to what degree of LDL cholesterol lowering 
is expected. High-intensity statins include atorvastatin (40 or 80 mg) and rosuvastatin (20 or 40 
mg). These lower LDL cholesterol concentrations by an estimated 50% or more. Moderate-
intensity statins include atorvastatin (10 or 20 mg), fluvastatin (40 mg twice daily), lovastatin (40 
mg), pravastatin (40 or 80 mg), rosuvastatin (5 or 10 mg) and simvastatin (20 or 40 mg). These 
affect LDL cholesterol by lowering concentrations by about 30 to 50%. Low-intensity statins 
include lovastatin (20 mg) and pravastatin (10 or 20 mg) and can lower LDL cholesterol 
concentrations by less than 30% (Gurgle & Blumenthal, 2017).   
Current Recommendations of Statin Use 
Recommendations for use of statins vary among different professional agencies. First, it 
is essential to determine which patients may be at an increased risk for developing CVD. Many 
divide their recommendations by stratifying patients based on their 10-year atherosclerotic 
cardiovascular disease (ASCVD) risk.  The American Heart Association (AHA) and American 
College of Cardiology (ACC) have developed a risk score calculator to help providers determine 
which patients may be at an increased risk of developing CVD. This calculator uses the patient’s 
age, race, sex, cholesterol levels, history of diabetes, use of hypertension treatment, smoking 
status to determine a patient’s risk score. DeFilippis, Young, and Blaha (2015) evaluated the 
most commonly used AHA/ACC ASCVD risk score with four other risk scores calculators to 
compare their efficacy. In the 4,227 patients with a mean age of 61.5 years were evaluated after 
an approximate ten-year follow up. The researchers discovered four out of the five risk 
stratification tools overestimated risk in men by 37% to 154%. Risk was overestimated for 
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women in three of the five tools by 46% to 67%. For example, there were 387 people who were 
predicted to have a 10% probability of having an ASCVD event according to the AHA/ACC 
ASCVD risk calculator during the ten-year study with 218 people having an event. ASCVD 
events were better predicted in women than in men. This brings up a possibility of 
overestimating a patient’s risk when using these calculators, but this is certainly better than 
underestimating. This study is a ten-year snapshot of a patient’s life, whereas it will be 
interesting to see trials with longer evaluation periods. 
After determining a patient’s increased risk, several organizations have recommendations 
on who should be taking statin medications. The United States Preventative Services Task Force 
(USPSTF) recommend the use of statins in the primary prevention of CVD with conditions 
deemed to increase the patient’s risk including diabetes, dyslipidemia, early cerebrovascular 
disease, hypertension, mild to moderate aortic stenosis, microalbuminuria, and elevated C-
reactive protein (CRP) levels. They state all adults aged 40 to 75 years without a prior history of 
CVD with one or more CVD risk factors and a calculated 10-year ACC/AHA ASCVD risk of 
10% or greater should be taking a low- to moderate-intensity statin for primary prevention 
purposes. They classify this recommendation as a Grade B Recommendation which suggests 
there is a high certainty of moderate benefit or there is moderate certainty of moderate to 
substantial benefit. If a patient has a lower ACC/AHA ASCVD risk below 10% but above 7.5%, 
statin use for primary prevention provides a smaller benefit. This is a Grade C Recommendation 
which allows the health professional to use their judgment on individual circumstances if 
recommending use would be beneficial to the patient (Chou, Dana, Blazina, Daeges, & Jeanne, 
2016).   
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Other recommendations for statin use have been proposed by the ACC and AHA. They 
highlight four groups that would benefit from statins including those with ASCVD, those who 
are greater than 21 years of age with LDL cholesterol levels greater than 190 mg/dL, those with 
diabetes mellitus who are between 40 and 75 years of age with LDL cholesterol levels between 
70 to 189 mg/dL, and those without ASCVD or diabetes or LDL cholesterol levels greater than 
190 mg/dL and an estimated 10-year ASCVD risk of greater than 7.5%. Prior to this report, it 
was suggested patients be treated to a specific goal LDL cholesterol target level. With this report, 
the ACC/AHA Expert Panel recommends using the maximum tolerated statin intensity. For 
primary prevention, they recommend at least a moderate-intensity statin in all cases falling into 
the statin benefit groups (Stone et al., 2014).  
When evaluating the differences among ACC/AHA and USPSTF recommendation 
statements, Pagidaipati (2017) looked at a sample of 3,416 subjects aged 40 to 75 years without 
prior CVD. In this population, 21.5% of the subjects were taking stating medications and an 
additional 15.8% of the subjects would be eligible based on the USPSTF guidelines compared to 
an additional 24.3% when looking at the ACC/AHA guidelines. Much of the discrepancy is due 
to the ACC/AHA guidelines recommending statin therapy in those with diabetes and the 
USPSTF guidelines do not. Others who were covered under the ACC/AHA guidelines but not 
the USPSTF guidelines included younger male smokers, younger males with dyslipidemia and 
younger women with obesity. 
The European Society of Cardiology (ESC) has yet another set of guidelines to determine 
if patients are at high risk of fatal CVD and should be taking statin medications in an effort of 
prevention. The ESC uses a risk stratification tool called the Systematic Coronary Risk 
Evaluation (SCORE) to determine the 10-year risk of fatal CVD rather than the use of the 
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ACC/AHA ASCVD risk tool commonly used in the United States. It bases its recommendation 
on the systolic blood pressure, age, gender, smoking status and total cholesterol as well as which 
country the patient lives in. Certain countries in Europe, including Denmark, France, Germany, 
Italy, Norway, Spain and others, are at a lower risk compared to countries such as Armenia, 
Bulgaria, Russia, and Ukraine. These differences in country of origin may be associated with 
diet, genetics, or other factors. Statin treatment is recommended in patients if the 10-year risk of 
fatal CVD is 5-10% and LDL-C is above 100 mg/dL or if the 10-year risk is greater than 10% 
and the LDL-C is above 70 mg/dL. Pavlovic et al. (2016) compared the ACC/AHA 
recommendation guidelines to that of the ESC. The study included 7,279 individuals without 
CVD and ages between 45 and 75 years. The ACC/AHA guidelines using the ASCVD risk 
calculator would recommend 58.9% of the patients be on a statin treatment, where the ESC 
guidelines would recommend 33.0% of the patients be treated with statins. The researchers 
discussed that many of those qualifying for the ACC/AHA guidelines but not the ESC guidelines 
were younger women with lower lipid profiles.  
Statin and Placebo Comparisons in Primary Prevention of Cardiovascular Disease 
It is well-known that statin medications decrease levels of LDL cholesterol. Several 
studies have evaluated the efficacy of statins in preventing cardiovascular effects in comparison 
to a placebo. Many of these trials have included patients with pre-existing conditions which 
qualify them for statin therapy in the primary prevention of CVD.  
Hypertension. 
In patients with pre-existing conditions putting them at an increased risk, statins may be 
of benefit. An elevated blood pressure puts a strain on the heart and can damage blood vessels 
possibly putting a patient at an increased risk of serious health problems including myocardial 
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infarction or a cerebrovascular accident. The researchers in the antihypertensive and lipid-
lowering treatment to prevent heart attack trial (ALLHAT) (2002) compared the use of 
pravastatin 40 mg, a moderate-intensity statin, to a usual care control group in the treatment of 
lipid-lowering and the effect on all-cause mortality. The randomized, nonblinded trial included 
subjects with hypertension with fasting LDL cholesterol levels of 120 to 189 mg/dL. The mean 
age of the population at the start of the study was 66 years, with 49% of the subjects being 
female and 41% of subjects being white. A total of 10,355 participants were included in the 
study and their treatment was evaluated for up to eight years. The researchers concluded there 
was no significant difference in all-cause mortality when comparing pravastatin treatment to 
usual care (p = 0.88). The rate of coronary heart disease was slightly lower in the pravastatin 
group (p = 0.16).  
Diabetes mellitus. 
Diabetes mellitus is another comorbidity that can increase a patient’s risk of developing 
CVD. Heljić, Velija, and Kulić (2009) evaluated the use of statins in the primary prevention of 
coronary heart disease in patients with pre-existing type 2 diabetes mellitus. The trial evaluated 
the levels of cholesterol as well as CRP in 95 subjects. CRP is an inflammatory marker which 
has been linked to atherosclerotic plaque formation in blood vessels. They excluded patients with 
serious comorbidities such as heart, liver, or kidney problems, hemoglobin A1c (HgbA1c) levels 
greater than ten percent, a body mass index greater than 35 kg/m2, and blood pressure greater 
than 140/90 mmHg. They split the subjects into two groups, one taking simvastatin 40 mg, a 
moderate intensity statin, and one taking a placebo. The mean age of the population was 61 years 
with 58% of the subjects being female. The researchers did not report the race of the subjects. 
After the one-year trial, the group taking simvastatin had significantly lower CRP levels than the 
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placebo group (p < 0.01). Coronary events were rarer in the simvastatin group (n = 3) than in the 
placebo group (n = 7). The researchers concluded that statin therapy reduced the risk of coronary 
heart disease by decreasing CRP levels. With only 95 subjects, it is difficult to compare and 
correlate the findings with trials exceeding 10,000 subjects. This study is beneficial in that it 
discusses the use of CRP to evaluate the efficacy of prevention of CVD.  
Another study performed by Knopp, d'Emden, Smilde, and Pocock (2006) evaluated the 
effects of atorvastatin 10 mg, a moderate-intensity statin, to a placebo in 2,410 subjects with type 
2 diabetes in a double-blind, placebo-controlled four-year study. The mean age of the population 
was 60 years with 38% of the subjects being female and 84% of subjects being white. They 
evaluated the two groups by assessing a primary cardiovascular end point by defining those who 
had a cardiovascular death, a nonfatal myocardial infarction, a nonfatal stroke, recanalization, 
coronary artery bypass surgery, a resuscitated cardiac arrest and worsening or unstable angina 
requiring hospitalization. The atorvastatin group noted a mean 29% LDL cholesterol reduction (p 
< 0.0001). In the group of patients who had not had a previous cardiac event, 10.4% of those 
taking atorvastatin and 10.8% of those treated by the placebo experienced a primary end point. 
The relative risk reduction was found to be 19% (p = 0.41). They concluded their results to be 
not statistically significant and could not determine a confirmed benefit of statin therapy in the 
primary prevention of CVD in patients with type 2 diabetes.  
In addition to diabetes, other comorbidities may put patients at a further increased risk of 
developing CVD. Colhoun et al. (2004) identified patients with type 2 diabetes who had at least 
one other comorbidity including hypertension, retinopathy, microalbuminuria, or currently 
smoking. Patients were excluded from the study if they had any history of myocardial infarction, 
angina, coronary vascular disease, cerebrovascular accident, or severe peripheral vascular 
STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE 16 
 
disease. A total of 2,838 patients were involved in the four-year trial. The mean age of the 
population was 62 years, with 32% of the subjects being female and 95% of subjects being 
white. Patients were divided into two groups; one taking atorvastatin 10 mg, a moderate intensity 
statin, and one taking a placebo. They observed a reduction of 36% in acute coronary events, 
31% decrease in coronary revascularization events, and 48% decrease in stroke in those taking 
the atorvastatin. The researchers also found in the atorvastatin group that a 37% reduction in 
major cardiovascular events (p = 0.001) and a 48% reduction in stroke occurred. Of note, the 
trial was ended early due to what the researchers felt was a significant reduction found on all-
cause mortality in the atorvastatin group. The researchers also describe significant effects on all-
cause mortality which promotes the use of statin therapy in the primary prevention of CVD in 
patients who may have multiple risk factors.  
Other risk factors.  
 Yusuf et al. (2016) evaluated effects of rosuvastatin 10 mg, a moderate-intensity statin, 
compared to a placebo on the primary prevention of cardiovascular events on patients with 
intermediate risk factors in a double-blinded, randomized trial in 228 centers in 21 countries. 
Participants in the trial were greater than 55 years of age if male or greater than 65 years of age if 
female and were required to have one of the following cardiovascular risk factors: elevated 
waist-to-hip ratio, history of a low level of HDL cholesterol, current or recent tobacco use, 
dysglycemia, family history of premature coronary artery disease, or mild renal dysfunction. The 
mean age of the population was 66 years, with 46% of the subjects being female and 20% of 
subjects being white.  After the seven-year study including 12,705 persons, the LDL cholesterol 
level was 34.7 mg/dL lower in the rosuvastatin group than in the placebo group (p < 0.001). An 
outcome or event was determined to be a cardiovascular death, a nonfatal stroke or a nonfatal 
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myocardial infarction. An event occurred in 3.7% of the participants in the rosuvastatin group 
and 4.8% of the participants in the placebo group (p=0.002). This resulted in a number needed to 
treat with rosuvastatin to prevent one event to be 91.  This study highlights a more multi-cultural 
participant population and noted no differences in findings across several backgrounds. With a 
moderate-intensity fixed-dose statin utilized in this study, it may indicate even a simple approach 
to treatment without monitoring may be effective. 
In evaluating the differences of statins in whites and nonwhites, Albert et al. (2011) 
evaluated an already completed a randomized, double-blind, placebo-controlled trial of 17,802 
subjects. The researchers compared rosuvastatin 20 mg, a high-intensity statin, to a placebo on 
their effects of LDL cholesterol and high-sensitivity C-reactive protein (hsCRP) levels. Subjects 
were all healthy at the start of the trial without prior known CVD, diabetes, or hyperlipidemia. 
The mean age of the population was 66 years, with 39% of the subjects being female and 71% of 
subjects being white. Results included a 45% reduction in cardiovascular events in whites and a 
37% reduction in nonwhites. This study included 5,117 nonwhite subjects which is much higher 
than many of the other studies. This may suggest statins are not as effective in the nonwhite 
population.  
Age should also be considered when evaluating if a patient should be taking a statin 
medication. It is well known that medications exert their effects differently in older individuals 
and with many of the side effects of statins including muscle problems and brain fogginess, it 
may be concerning to have these effects increased in the elderly population as it could have the 
potential to result in negative effects on function and may increase the risk for falls or other 
catastrophic events. Han et al. (2017) evaluated the patients in the ALLHAT trial who were 65 
years of age and older without ASCVD at the start of the trial. In the 2,867 patients evaluated, 
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more participants died in the pravastatin group when compared to the usual care group in ages 65 
to 74 years (p=0.55) as well as those older than 75 years (p = 0.07). They concluded that statin 
use for primary prevention did not have a benefit on all-cause mortality or coronary heart disease 
when comparing to usual care in patients older than 65 years of age. Although a nonsignificant 
correlation, they did note an increase in all-cause mortality with the use of pravastatin in those 
greater than 75 years. After one year, 8.3% of the usual care group were taking a statin and this 
increased to 29% in the sixth year.  
As noted with the comparison of the ESC guidelines in other countries to the ACC/AHA 
and USPSTF guidelines, it is known that statins are used much more frequently in the United 
States than in other countries. It is not known if this is due to the American diet and lifestyle or if 
other countries are not utilizing the medication as frequently. Nakamura et al. (2006) performed 
a study to evaluate if research done on western populations can be applied to patient in Japan, 
where the rate of CVD is much lower. The randomized, blinded study included 7,832 patients 
with preexisting hyperlipidemia were split into a diet group and a diet plus pravastatin group. 
The mean age of the population was 58 years with 69% of the subjects being female. Pravastatin 
10 mg, a low-intensity statin, was administered initially to the treatment group and adjusted up to 
40 mg if deemed to be appropriate by the treating physician. Coronary heart disease and cerebral 
infarction occurred at a significantly lower rate in the pravastatin group (p = 0.005). The rate of 
all cardiovascular events was also significantly lower in the pravastatin group (p = 0.01). The 
researchers found the number needed to treat to prevent one coronary heart disease event was 
119 in the Japanese subjects. Although the trial used a low-intensity statin, the researchers 
deemed there was a significant benefit in the use of statin therapy in patients with 
hyperlipidemia. 
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Vascular effects of statin medications. 
The thickness of the vessels, specifically the carotid intima-media thickness (IMT), and 
the left ventricular mass has also been proposed to evaluate the benefits of statins. Increased 
carotid IMT has been shown to be predictive of the development of coronary artery disease, 
stroke, and coronary atherosclerosis. Anderssen, Hjelstuen, Hjermann, Bjerkan, and Holme 
(2005) performed a study in 568 drug-treated hypertensive subjects over the course of four years. 
The mean age of the population was 57 years with all subjects being male. There were four 
groups evaluated in the study. One group was given fluvastatin 40 mg, a low-intensity statin, 
another group was given a placebo, a third group was given fluvastatin and instructed on lifestyle 
interventions and a final group was given a placebo and given lifestyle interventions. The 
lifestyle interventions included physical activity as well as dietary intervention programs. When 
evaluating the effect of fluvastatin alone to the placebo, there was significantly reduced 
progression in common carotid artery IMT (p = 0.0297). Fluvastatin also significantly reduced 
the progression of common carotid artery IMT when comparing the groups of fluvastatin with 
lifestyle intervention and those with only lifestyle interventions (p = 0.0214). The left ventricular 
mass in placebo-treated patients increased by 30.4 grams over the course of the trial. This 
increase in mass did not occur with subjects being treated with fluvastatin which was found to be 
statistically significant (p = 0.0144).  
Another study evaluating the carotid intima-media thickness was performed on patients 
with type 2 diabetes mellitus. Beishuizen (2004) evaluated 250 diabetic patients in their trial. The 
mean age of the population was 59 years, with 53% of the subjects being female and 68% of 
subjects being white. The subjects were divided evenly into a statin group and placebo group. 
The statin group started on cerivastatin 0.4 mg which was switched to simvastatin 20 mg, a 
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moderate-intensity statin, in the middle of the study when cerivastatin was withdrawn from the 
market. LDL cholesterol increased by 8% in the placebo group and was reduced by 25% in the 
statin group (p < 0.001). The carotid IMT in the placebo group was 0.780 mm at baseline and 
0.774 mm at two years (p = 0.50), while the carotid IMT in the statin group was 0.763 mm at 
baseline and 0.765 mm at two years (p = 0.78). There was no statistically significant change in 
the IMT when comparing the two groups (p = 0.48). They concluded atherosclerosis progression, 
when evaluating common carotid IMT, was mild in both groups, which they stated was 
unexpected. They did describe a significant lowering of LDL cholesterol with the use of the 
moderate-intensity statin, which would be expected.  
Safety of Long-Term Statin Use 
 When utilizing a medication in the primary prevention of disease, it is important to 
evaluate the safety of the medication as the risk versus benefit in patients should always be 
considered. When looking at adverse effects of statin medications, Collins et al. (2016) 
concluded in 10,000 patients, there may be 5 cases of myopathy, 50 to 100 new cases of diabetes 
mellitus, and 5 to 10 hemorrhagic strokes. These adverse effects were deemed to be minimal 
compared to the possible risks of not taking a statin, such as having a fatal cardiovascular event. 
 In patients taking statins, Crandall et al. (2017) discuss the incidence of diabetes in 
patients who are not diabetic and start a statin medication. They performed a trial with 3,234 
participants who were older than 25 years of age, had a BMI greater than 24 kg/m2 and had 
fasting plasma glucose levels between 95 and 125 mg/dL as well as an impaired glucose 
tolerance test. Participants were assigned to one of three groups including intensive lifestyle 
interventions, metformin, or a placebo. After 10 years, 33 to 37% of subjects had started a statin 
medication prior to their diabetes diagnosis, most commonly simvastatin or atorvastatin. The 
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researchers concluded that statin use may be a risk factor for developing diabetes in patients who 
are at high risk. They suggested if statins are started on a high-risk patient, that the patient is 
monitored closely.  This study discusses the use of statin therapy in patients who are at a high 
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III. Discussion 
Cardiovascular disease (CVD) is a leading cause of death in the United States in both 
men and women. The medical community is continuously looking for methods of preventing 
CVD and keeping patients healthy. One constant in the research has been the development of 
atherosclerotic plaques when there are elevated levels of cholesterol in the blood. The exact 
cause of the development of the plaques is unknown, but lower levels of cholesterol often lead to 
lower atherosclerotic plaque formation, which in turn reduces the risk for having a 
cardiovascular event. Statin medications have long been known to decrease cholesterol levels by 
decreasing the rate-limiting enzyme, HMG-CoA reductase, in the formation of cholesterol. With 
this information, statin have been prescribed to prevent cardiovascular events, especially in those 
with a history of CVD, also known as secondary prevention. In primary prevention, or 
attempting to prevent CVD before it occurs, it has been difficult to determine if the widespread 
population-based use of statins recommended by several health organizations is resulting in 
decreased risk of developing cardiovascular disease.  
The American College of Cardiology (ACC) and the American Heart Association (AHA) 
developed a risk assessment calculator to determine a person’s risk of developing cardiovascular 
disease. This risk is based on age, race, blood pressure, levels of low-density lipoprotein, and 
other comorbidities such as diabetes mellitus and hypertension. DeFilippis et al. (2015) 
concluded this calculator, along with other CVD risk calculators, may be overestimating risk by 
25 to 152 percent. The United States Preventative Services Task Force (USPSTF) uses the 
ACC/AHA risk assessment tool to predict whether statin medications will be beneficial to a 
patient population. A risk of 10% or higher deems a patient should be taking a low- to moderate- 
intensity statin (Chou et al., 2016). The ACC/AHA also recommends at least a moderate-
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intensity statin in patients who are greater than 21 years of age with LDL cholesterol levels 
greater than 190 mg/dL, those with diabetes mellitus who are between 40 and 75 years of age 
with LDL cholesterol levels between 70 to 189 mg/dL, and those without ASCVD or diabetes or 
LDL cholesterol levels greater than 190 mg/dL and an estimated 10-year ASCVD risk of greater 
than 7.5% (Stone et al., 2014). The use of these population-based tools to determine the 
likelihood of a medication helping a certain patient has been under scrutiny in recent years. Each 
of these recommendation statements differs and some patients may be a candidate for statins 
with one tool, but not the other. Pagidaipati (2017) evaluated the differences in these two 
recommendation statements and concluded in those not taking statins, an additional 15.8% of the 
subjects would be eligible based on the USPSTF guidelines compared to an additional 24.3% 
when looking at the ACC/AHA guidelines. Much of the discrepancy is due to the ACC/AHA 
guidelines recommending statin therapy in those with diabetes and the USPSTF guidelines do 
not. The inconsistency of these recommendation statements can make it confusing for providers 
who may be prescribing these medications.  
A study performed by Heljić et al. (2009) evaluated patients with diabetes mellitus and 
compared the effects of a moderate-intensity statin and a placebo on CRP levels in 95 patients. 
After the one-year trial, the group taking simvastatin had significantly lower CRP levels than the 
placebo group (p < 0.01). Although this study had only 95 patients, it does bring up the 
possibility of evaluating CRP levels as a means to predict potential cardiovascular events. This 
study also was only performed over the course of one year, which may not be enough to 
determine if there is an effect on prevention of cardiovascular events. In contrast, another study 
performed on diabetic patients, assessed the primary cardiovascular end point in 2,410 subjects. 
In the four-year study, 10.4% of those taking the moderate-intensity statin and 10.8% of those 
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treated by the placebo experienced a primary end point. The relative risk reduction was found to 
be 19% (p = 0.41). They concluded their results to be not statistically significant and could not 
determine a confirmed benefit of statin therapy in the primary prevention of CVD in patients 
with diabetes (Knopp et al., 2006). With diabetes being the inconsistency between the USPSTF 
guidelines and the ACC/AHA guidelines, this study brings up the possibility of statins not being 
as beneficial to patients with diabetes and no other comorbidities. When evaluating diabetes 
patients who do have other comorbidities such as hypertension, retinopathy, microalbuminuria, 
or currently smoking, Colhoun et al. (2004) evaluated 2,838 patients over a four-year trial while 
the patients were taking either a moderate intensity statin or a placebo. They observed a 
reduction of 36% in acute coronary events, 31% decrease in coronary revascularization events, 
and 48% decrease in stroke in those taking the atorvastatin. The researchers also found in the 
atorvastatin group that a 37% reduction in major cardiovascular events (p = 0.001) and a 48% 
reduction in stroke occurred. Of note, the trial was ended early due to what the researchers felt 
was a significant reduction found on all-cause mortality in the statin group. The researchers also 
describe significant effects on all-cause mortality which promotes the use of statin therapy in the 
primary prevention of CVD in patients who may have multiple risk factors. It is these multiple 
risk factors that are not included in the ACC/AHA risk assessment tool that may increase certain 
patients risk even further, but those without multiple risk factors may have an overestimated risk.   
In addition to diabetes, other conditions noted to increase risk have been evaluated by 
researchers. Yusuf et al. (2016) evaluated effects of a moderate-intensity statin compared to a 
placebo on the primary prevention of cardiovascular events on patients with intermediate risk 
factors such as elevated waist-to-hip ratio, history of a low level of HDL cholesterol, current or 
recent tobacco use, dysglycemia, family history of premature coronary artery disease, or mild 
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renal dysfunction.  After the seven-year study including 12,705 persons, an event occurred in 
3.7% of the participants in the rosuvastatin group and 4.8% of the participants in the placebo 
group (p=0.002). This resulted in a number needed to treat with rosuvastatin to prevent one event 
to be 91.  This study was performed in a number of different centers across multiple countries 
and represents a more multi-cultural participant population and noted no differences in findings 
across several backgrounds. Albert et al. (2011) found conflicting results when evaluating 17,802 
subjects with a number of nonwhite subjects. With 5,117 nonwhite subjects, they noted more 
nonwhite subjects than many of the other similar studies. Results included a 45% reduction in 
cardiovascular events in whites and a 37% reduction in nonwhites. This may suggest statins are 
not as effective in the nonwhite population. Further research is needed in this area.  
Other ethnic groups may also see different benefits from the use of statin medications. 
The Nakamura et al. (2006) study aimed to evaluate if research done on western populations can 
be applied to patients in Japan, where the rate of CVD is much lower. Coronary heart disease and 
cerebral infarction occurred at a significantly lower rate in the statin group (p = 0.005). The rate 
of all cardiovascular events was also significantly lower in the statin group (p = 0.01). The 
number needed to treat to prevent one coronary heart disease event was 119 in the Japanese 
subjects with hyperlipidemia. Although the trial used a low-intensity statin, the researchers 
deemed there was a significant benefit in the use of statin therapy in patients with 
hyperlipidemia. These patients did not have other comorbidities such as hypertension or diabetes 
which would potentially increase their risk of cardiovascular events.  
Age should also be considered when evaluating if a patient should be taking a statin 
medication. It is well known that medications exert their effects differently in older individuals 
and with many of the side effects of statins including muscle problems and brain fogginess, it 
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may be concerning to have these effects increased in the elderly population as it could have the 
potential to result in negative effects on function and may increase the risk for falls or other 
catastrophic events. Han et al. (2017) evaluated a trial of 2,867 patients over the age of 65 and 
found that more participants died in the statin group when compared to the usual care group in 
ages 65 to 74 years (p=0.55) as well as those older than 75 years (p = 0.07). The researchers 
concluded that statin use for primary prevention did not have a benefit on all-cause mortality or 
coronary heart disease when comparing to usual care in patients older than 65 years of age. Age 
is certainly a factor to be considered when starting a patient on a new medication, especially if 
the goal is the prevention of atherosclerotic cardiovascular disease which may already be present 
at an older age.  
Although it is unknown how atherosclerotic plaques form, some researchers have 
evaluated the thickness of the vessels, specifically the carotid intima-media thickness (IMT) as a 
way to predict CVD. Increased carotid IMT has been shown to be predictive of the development 
of coronary artery disease, stroke, and coronary atherosclerosis. In a four-year study comparing a 
low-intensity statin to a placebo, there was significantly reduced progression in common carotid 
artery IMT (p = 0.0297). Anderssen et al. (2005) also found the left ventricular mass in placebo-
treated patients increased by 30.4 grams over the course of the trial which did not occur in the 
568 drug-treated hypertensive subjects (p = 0.0144).  Comparing this trial to one performed on 
patients with diabetes mellitus, Beishuizen (2004) evaluated 250 diabetic patients and discovered 
the carotid IMT in the placebo group was 0.780 mm at baseline and 0.774 mm at two years (p = 
0.50), while the carotid IMT in the statin group was 0.763 mm at baseline and 0.765 mm at two 
years (p = 0.78). There was no statistically significant change in the IMT when comparing the 
two groups (p = 0.48). They concluded atherosclerosis progression, when evaluating common 
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carotid IMT, was mild in both groups, which they stated was unexpected. They did describe a 
significant lowering of LDL cholesterol with the use of the moderate-intensity statin, which 
would be expected. This again brings up the possibility of statin medications not being as helpful 
in patients with diabetes as discussed earlier with the Knopp et al. (2006) trial.  
A concern with many of the trials discussed is that the length is often only a few years. 
The increase of statin prescribing in recent years is concerning due to the lack of research on the 
safety of long-term statin use. Providers will need to know the long-term safety of the medication 
when assessing the risk versus benefit in their patients. When looking at adverse effects of statin 
medications, Collins et al. (2016) concluded in 10,000 patients, there may be 5 cases of 
myopathy, 50 to 100 new cases of diabetes mellitus, and 5 to 10 hemorrhagic strokes. These 
adverse effects were deemed to be minimal compared to the possible risks of not taking a statin, 
such as having a fatal cardiovascular event. Conversely, Crandall et al. (2017) assessed the 
incidence of diabetes in patients who are not diabetic and start a statin medication. In 3,234 
participants who were older than 25 years of age, had a BMI greater than 24 kg/m2 and had 
fasting plasma glucose levels between 95 and 125 mg/dL as well as an impaired glucose 
tolerance test, 33 to 37% of subjects had started a statin medication prior to their diabetes 
diagnosis over a ten-year period. The researchers concluded that statin use may be a risk factor 
for developing diabetes in patients who are at high risk. They suggested if statins are started on a 
high-risk patient, that the patient is monitored closely.  
In conclusion, studies still seem to lack true evidence of a reduction cardiovascular events 
when starting a statin. It is difficult to assess the efficacy of a medication when evaluating its 
prevention abilities, so it may be more beneficial for providers to prescribe this medication on a 
case by case basis rather than the population-based recommendation guidelines set out by the 
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USPSTF and ACC/AHA. Certain population, such as those with diabetes, may not see as much 
benefit in starting a statin, especially if there are no other comorbidities in the patient. Patients 
should continue to be monitored for long-term side effects as the safety of extended 
administration of these medications is still under investigation as the rate of prescribing is 
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IV. Applicability of Clinical Practice 
The research assessed in this project identifies some discrepancies among 
recommendation guidelines on the prescription of statin medications in the primary prevention of 
cardiovascular disease. It is important for providers to be aware of these recommendation 
guidelines, but to also assess each patient’s individual health status and risk assessment. The risk 
assessment tools do not take into consideration important factors such as diet and exercise, 
family history, or other comorbidities which may increase or decrease a patient’s risk of 
cardiovascular disease. The research showed benefit in some populations, including those with 
multiple risk factors. Other populations, such as those with diabetes, did not have a significant 
benefit which falls against that of the American College of Cardiology (ACC) and American 
Heart Association (AHA) recommendation guidelines. Providers can use this information to 
make decisions together with their patients on whether a statin prescription is appropriate. The 
prescribing of statin medications has increased exponentially in recent years, making them one of 
the most commonly prescribed medications in the United States. Their use is relatively new to 
the pharmaceutical world as they were first introduced in 1987. Long-term use, such as greater 
than 15 years, of these medications, have yet to be evaluated and is also a consideration 
providers should take into account when discussing risks with their patients. As patients are 
diagnosed with conditions such as diabetes at much younger ages, long-term use of statins will 
become more dominant. Side effects should be frequently discussed and risks should be assessed 
regularly to determine if removing the medication would be appropriate. Providers must assess 
each patient’s benefits versus risk to determine if a statin prescription may have an effect on the 
primary prevention of cardiovascular disease. With greatest benefit seen in patients with multiple 
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risk factors, patients with single risk factors may have the greatest effect in the risk versus 
benefit discussion when determining statin appropriateness in patient care. 
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